RecruitingPhase 1/2

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

United States60 participantsStarted 2025-07-29

Plain-language summary

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Have received at least one prior regimen in metastatic setting (2L+ NSCLC). Participants with actionable tumor alterations should have received targeted therapy if locally available OR
✓. Have not received systemic therapy (1L NSCLC) and have PD-L1 expression ≥ 1%.
✓. Have not received systemic therapy (1L NSCLC) and have PD-L1 expression ≥ 1%.

What they're measuring

Safety- Part 1A & Part 2A (dose escalation) and Part 2B (dose expansion)

Timeframe: Measured from the informed consent until Day 90 post-last dose.

Efficacy- Part 2B only (dose expansion)

Timeframe: Measured every 6 weeks for 48 weeks and every 12 weeks thereafter from first dose until disease progression or death in the absence of disease progression(approximately 2 years)

Trial details

NCT IDNCT07115043

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2029-10-02

Contact for this trial

AstraZeneca Clinical Study Information Center

1-877-240-9479 information.center@astrazeneca.com

View on ClinicalTrials.gov More Melanoma trials